4-甲基-2-羟基嘧啶-5-羧酸乙酯 | 6214-64-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-甲基-2-羟基嘧啶-5-羧酸乙酯
• 中文别名: 4-甲基-2-羟基嘧啶-5-甲酸乙酯；2-羟基-4-甲基-5-吡啶羧酸乙酯
• 英文名称: 6-methyl-2-oxo-1,2-dihydropyrimidine-5-carboxylic acid ethyl ester
• 英文别名: ethyl 1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate；ethyl 6-methyl-2-oxo-1,2-dihydropyrimidine-5-carboxylate；6-methyl-2-oxo-1,2-dihydro-pyrimidine-5-carboxylic acid ethyl ester；ethyl 6-methyl-2-oxo-1H-pyrimidine-5-carboxylate
• CAS: 6214-64-8
• 化学式: C₈H₁₀N₂O₃
• mdl: MFCD01875049
• 分子量: 182.179
• InChiKey: UNZAXNKEIQRZBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252 °C
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-甲基-2-羟基嘧啶-5-羧酸乙酯 在 碘 、 magnesium 作用下， 以 甲醇 为溶剂， 反应 30.0h， 以62%的产率得到6-甲基-2-氧代-1,2,3,4-四氢嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  镁/甲醇：一种化学选择性还原嘧啶-2（1 H）-ones的有效还原剂

  摘要：

  甲醇中的镁是化学选择性还原嘧啶2（1 H）-ones的有效试剂。其他可还原的官能团，例如烯胺酯和乌里多羰基的酯和烯烃，不受影响。这构成了通过嘧啶-2（1 H）-one的还原形成Biginelli 3,4-dihydropyrimidin-2（1 H）one的第一个例子。

  DOI：

  10.1016/j.tetlet.2009.02.165
• 作为产物：
  描述：

  乙酰乙酸乙酯 在 硝酸 、 氯化铵 作用下， 反应 3.5h， 生成 4-甲基-2-羟基嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  Synthesis of 4-aminoquinoline–pyrimidine hybrids as potent antimalarials and their mode of action studies

  摘要：

  One of the most viable options to tackle the growing resistance to the antimalarial drugs such as artemisinin is to resort to synthetic drugs. The multi-target strategy involving the use of hybrid drugs has shown promise. In line with this, new hybrids of quinoline with pyrimidine have been synthesized and evaluated for their antiplasmodial activity against both CQ(S) and CQ(R) strains of Plasmodium falciparum. These depicted activity in nanomolar range and were found to bind to heme as well as AT rich pUC18 DNA. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.05.046

文献信息

• [EN] NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016037578A1

  公开（公告）日：2016-03-17

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，这些化合物是重排转位过程中的抑制剂（RET）激酶，包含它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病和/或与RET功能障碍相关的疾病或调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道氏综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和食管胃交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• [EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
  申请人：RQX PHARMACEUTICALS INC

  公开号：WO2017084630A1

  公开（公告）日：2017-05-26

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本文提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制细菌类型1信号肽酶（SpsB）发挥作用，这是细菌中的一种必需蛋白质。还提供了使用所述化合物的药物组合物和治疗方法。
• [EN] PYRIMIDINE AMIDE COMPOUNDS<br/>[FR] COMPOSÉS PYRIMIDINE AMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012123467A1

  公开（公告）日：2012-09-20

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的化合物为式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，例如哮喘和慢性阻塞性肺病（COPD）等，具有实用性。
• Pyrimidine carboxylates and related compounds and methods for treating
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US05935966A1

  公开（公告）日：1999-08-10

  Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

  本文披露了作为抗炎药物的效用的化合物，特别是用于预防和/或治疗免疫炎症和自身免疫疾病的化合物。这些化合物是含嘧啶的化合物，在一个实施例中，它们是相同的酯。还披露了通过向需要的动物施用本发明的化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症病症的方法。
• Pyrimidine carboxamides and related compounds and methods for treating
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US05811428A1

  公开（公告）日：1998-09-22

  Compounds having utility as antinflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine- or pyrazine-containing compounds and, in one embodiment, are carboxyamides of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

  本发明揭示了作为抗炎药物一般以及更具体地用于预防和/或治疗免疫炎症性和自身免疫性疾病的有用化合物。这些化合物是含有嘧啶或吡嗪的化合物，在一个实施例中，它们是相同的羧酰胺。还揭示了通过向需要的动物投与本发明化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症性疾病的方法。